IELO, CLAUDIA
IELO, CLAUDIA
DIPARTIMENTO DI MEDICINA MOLECOLARE
A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC)
2025 Laganà, Alessandro; Ielo, Claudia; Buffolino, Sonia; Di Lascio, Attilio; Bizzoni, Luisa; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Diverio, Daniela; Breccia, Massimo
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib
2025 Laganà, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Sorella, S.; Ielo, C.; Zhdanovskaya, N.; Martelli, M.; Breccia, M.
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
2023 Masucci, Chiara; Passucci, Mauro; Scalzulli, Emilia; Carmosino, Ida; Capriata, Marcello; Costa, Alessandro; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo
Case Report: Infectious prophylaxis in hematological malignancies
2023 Passucci, Mauro; Masucci, Chiara; Paoletti, Francesca; Ielo, Claudia; Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Martelli, Maurizio; Gentile, Giuseppe; Breccia, Massimo
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases
2023 Iaquinta, G.; Scalzulli, E.; Angeloni, S.; Carmosino, I.; Costa, A.; Ielo, C.; Passucci, M.; Masucci, C.; Grammatico, P.; Breccia, M.; Martelli, M.
Clinical and biological advances of critical complications in acute myeloid leukemia
2025 Costa, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Ielo, Claudia; Bisegna, Maria Laura; Martelli, Maurizio; Breccia, Massimo
Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX)
2025 Laganà, Alessandro; Scalzulli, Emilia; Bisegna, Maria Laura; Carmosino, Ida; Ielo, Claudia; Andriola, Costanza; Martelli, Maurizio; Breccia, Massimo
CML-473: Treatment-Free Remission (TFR) in Chronic-Phase Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Scoring System for Molecular Recurrence
2025 Laganà, Alessandro; Scalzulli, E; Carmosino, I; Bisegna, M Laura; Ielo, C; Diverio, D; Martelli, Maurizio; Breccia, M
Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time
2024 Scalzulli, E.; Costa, A.; Carmosino, I.; Musiu, P.; Bisegna, M. L.; De Propris, M. S.; Ielo, C.; Diverio, D.; Minotti, C.; Capria, S.; Latagliata, R.; Martelli, M.; Breccia, M.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
2021 Tedeschi, A.; Frustaci, A. M.; Mauro, F. R.; Chiarenza, A.; Coscia, M.; Ciolli, S.; Reda, G.; Laurenti, L.; Varettoni, M.; Murru, R.; Barate, C.; Sportoletti, P.; Greco, A.; Borella, C.; Rossi, V.; Deodato, M.; Biagi, A.; Zamprogna, G.; Pelle, A. C.; Lapietra, G.; Vitale, C.; Morelli, F.; Cassin, R.; Fresa, A.; Cavalloni, C.; Postorino, M.; Ielo, C.; Cairoli, R.; Di Raimondo, F.; Montillo, M.; Del Poeta, G.
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort
2023 Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Minotti, Clara; Stefania De Propris, Maria; Masucci, Chiara; Passucci, Mauro; Laura Bisegna, Maria; Ielo, Claudia; Pepe, Sara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo
Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation
2025 Lagana, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Ielo, C.; Diverio, D.; Martelli, M.; Breccia, M.
Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applications
2025 Ielo, C.; Breccia, M.
Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia
2025 Latagliata, R.; Carmosino, I.; Di Veroli, A.; Scalzulli, E.; Ielo, C.; De Angelis, G.; Laureana, R.; De Gregoris, C.; Bisegna, M. L.; Trape, G.; Martelli, M.; Breccia, M.
Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib
2025 Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Ielo, Claudia; Andriola, Costanza; Martelli, Maurizio; Breccia, Massimo
Innovative approaches in chronic myeloid leukemia: from liquid biopsy to genomic characterization beyond BCR::ABL1
2026 Ielo, Claudia
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
2024 Lagana, Alessandro; Passucci, Mauro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Costa, Alessandro; Bisegna, Maria Laura; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission
2023 Laganà, Alessandro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Passucci, Mauro; Ielo, Claudia; Costa, Alessandro; Masucci, Chiara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
2024 Costa, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Ielo, Claudia; Bisegna, Maria Laura; Martelli, Maurizio; Breccia, Massimo
POSTER: CML-473 Treatment-Free Remission (TFR) in Chronic-Phase Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Scoring System for Molecular Recurrence
2025 Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Ielo, Claudia; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC) | 2025 | Laganà, Alessandro; Ielo, Claudia; Buffolino, Sonia; Di Lascio, Attilio; Bizzoni, Luisa; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Diverio, Daniela; Breccia, Massimo | |
| Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib | 2025 | Laganà, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Sorella, S.; Ielo, C.; Zhdanovskaya, N.; Martelli, M.; Breccia, M. | |
| Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination | 2023 | Masucci, Chiara; Passucci, Mauro; Scalzulli, Emilia; Carmosino, Ida; Capriata, Marcello; Costa, Alessandro; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo | |
| Case Report: Infectious prophylaxis in hematological malignancies | 2023 | Passucci, Mauro; Masucci, Chiara; Paoletti, Francesca; Ielo, Claudia; Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Martelli, Maurizio; Gentile, Giuseppe; Breccia, Massimo | |
| CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases | 2023 | Iaquinta, G.; Scalzulli, E.; Angeloni, S.; Carmosino, I.; Costa, A.; Ielo, C.; Passucci, M.; Masucci, C.; Grammatico, P.; Breccia, M.; Martelli, M. | |
| Clinical and biological advances of critical complications in acute myeloid leukemia | 2025 | Costa, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Ielo, Claudia; Bisegna, Maria Laura; Martelli, Maurizio; Breccia, Massimo | |
| Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX) | 2025 | Laganà, Alessandro; Scalzulli, Emilia; Bisegna, Maria Laura; Carmosino, Ida; Ielo, Claudia; Andriola, Costanza; Martelli, Maurizio; Breccia, Massimo | |
| CML-473: Treatment-Free Remission (TFR) in Chronic-Phase Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Scoring System for Molecular Recurrence | 2025 | Laganà, Alessandro; Scalzulli, E; Carmosino, I; Bisegna, M Laura; Ielo, C; Diverio, D; Martelli, Maurizio; Breccia, M | |
| Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time | 2024 | Scalzulli, E.; Costa, A.; Carmosino, I.; Musiu, P.; Bisegna, M. L.; De Propris, M. S.; Ielo, C.; Diverio, D.; Minotti, C.; Capria, S.; Latagliata, R.; Martelli, M.; Breccia, M. | |
| Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? | 2021 | Tedeschi, A.; Frustaci, A. M.; Mauro, F. R.; Chiarenza, A.; Coscia, M.; Ciolli, S.; Reda, G.; Laurenti, L.; Varettoni, M.; Murru, R.; Barate, C.; Sportoletti, P.; Greco, A.; Borella, C.; Rossi, V.; Deodato, M.; Biagi, A.; Zamprogna, G.; Pelle, A. C.; Lapietra, G.; Vitale, C.; Morelli, F.; Cassin, R.; Fresa, A.; Cavalloni, C.; Postorino, M.; Ielo, C.; Cairoli, R.; Di Raimondo, F.; Montillo, M.; Del Poeta, G. | |
| Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort | 2023 | Costa, Alessandro; Carmosino, Ida; Scalzulli, Emilia; Minotti, Clara; Stefania De Propris, Maria; Masucci, Chiara; Passucci, Mauro; Laura Bisegna, Maria; Ielo, Claudia; Pepe, Sara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo | |
| Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation | 2025 | Lagana, A.; Scalzulli, E.; Carmosino, I.; Bisegna, M. L.; Ielo, C.; Diverio, D.; Martelli, M.; Breccia, M. | |
| Extracellular vesicles as source of biomarkers in hematological malignancies: looking towards clinical applications | 2025 | Ielo, C.; Breccia, M. | |
| Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia | 2025 | Latagliata, R.; Carmosino, I.; Di Veroli, A.; Scalzulli, E.; Ielo, C.; De Angelis, G.; Laureana, R.; De Gregoris, C.; Bisegna, M. L.; Trape, G.; Martelli, M.; Breccia, M. | |
| Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib | 2025 | Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Ielo, Claudia; Andriola, Costanza; Martelli, Maurizio; Breccia, Massimo | |
| Innovative approaches in chronic myeloid leukemia: from liquid biopsy to genomic characterization beyond BCR::ABL1 | 2026 | Ielo, Claudia | |
| Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation | 2024 | Lagana, Alessandro; Passucci, Mauro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Costa, Alessandro; Bisegna, Maria Laura; Ielo, Claudia; Martelli, Maurizio; Breccia, Massimo | |
| One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission | 2023 | Laganà, Alessandro; Pepe, Sara; Scalzulli, Emilia; Carmosino, Ida; Passucci, Mauro; Ielo, Claudia; Costa, Alessandro; Masucci, Chiara; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo | |
| Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors | 2024 | Costa, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Ielo, Claudia; Bisegna, Maria Laura; Martelli, Maurizio; Breccia, Massimo | |
| POSTER: CML-473 Treatment-Free Remission (TFR) in Chronic-Phase Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Scoring System for Molecular Recurrence | 2025 | Laganà, Alessandro; Scalzulli, Emilia; Carmosino, Ida; Bisegna, Maria Laura; Ielo, Claudia; Diverio, Daniela; Martelli, Maurizio; Breccia, Massimo |